Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
S-3ASR
Regulatory Filings Classification · 90% confidence The document is a Securities Act registration statement (Form S-3) and accompanying prospectus for Insmed Incorporated filed with the SEC. It is not an annual or interim report, earnings release, management announcement, or other narrowly defined filing in our taxonomy. Registration statements and prospectuses fall under general regulatory disclosures and do not match any more specific category. Therefore, the correct classification is Regulatory Filings (RNS).
2026-05-15 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 89% confidence The document is a current report on Form 8-K filed under Item 5.07 (“Submission of Matters to a Vote of Security Holders”) presenting the detailed voting results for proposals at the company’s Annual Meeting of shareholders. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-15 English
8-K - INSMED Inc (0001104506) (Filer)
Report Publication Announcement Classification · 85% confidence The document is a short Form 8-K (under 5,000 characters) whose primary function is to furnish an earnings press release and slide presentation as exhibits. It does not contain the financial results itself, but rather announces and attaches those materials. Under the “menu vs meal” rule, this is an announcement of the publication/filing of reports, not the reports themselves. Therefore it should be classified as a Report Publication Announcement (RPA).
2026-05-07 English
10-Q - INSMED Inc (0001104506) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - INSMED Inc (0001104506) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on a press release announcing topline efficacy and safety results from a Phase 2b clinical study. It includes study details, results, and a statement about discontinuing the development program. There are no comprehensive financial statements or detailed financial analysis typical of annual or quarterly reports. The document is not a transcript, proxy, or governance report. It is an event-driven disclosure about clinical trial results and related corporate decisions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-04-07 English
ARS - INSMED Inc (0001104506) (Filer)
Annual Report
2026-04-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.